News
-
-
PRESS RELEASE
invIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journal
invIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journal. Study demonstrates safety and immune system enhancements for solid tumors -
-
-
-
-
-
-
-
PRESS RELEASE
invIOs selects INV501 lead candidate to progress into IND-enabling studies in glioblastoma and melanoma
invIOs selects INV501 lead candidate to progress into IND-enabling studies in glioblastoma and melanoma. The compound shows strong activation of tumor-specific T cells in preclinical testing
